.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Citi
Boehringer Ingelheim
Novartis
Julphar
UBS
Deloitte
Fish and Richardson
Accenture
Moodys

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,862,833

« Back to Dashboard

Which drugs does patent 7,862,833 protect, and when does it expire?


Patent 7,862,833 protects FENTORA and is included in one NDA. There has been one Paragraph IV challenge on Fentora.

This patent has fifty-eight patent family members in twenty-seven countries.

Summary for Patent: 7,862,833

Title:Effervescent oral opiate dosage forms and methods of administering opiates
Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.
Inventor(s): Moe; Derek (Maple Grove, MN)
Assignee: Cima Labs, Inc. (Eden Prairie, MN)
Application Number:11/026,759
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Delivery; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-001Sep 25, 2006RXYesNo7,862,833► SubscribeY
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-002Sep 25, 2006RXYesNo7,862,833► SubscribeY
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-003Sep 25, 2006RXYesYes7,862,833► SubscribeY
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-004Sep 25, 2006RXYesNo7,862,833► SubscribeY
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-005Sep 25, 2006RXYesNo7,862,833► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,862,833

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,119,158Effervescent oral fentanyl dosage form and methods of administering fentanyl► Subscribe
7,858,121Effervescent oral fentanyl dosage form and methods of administering fentanyl► Subscribe
8,298,577Effervescent oral opiate dosage forms and methods of administering opiates► Subscribe
8,092,832Generally linear effervescent oral fentanyl dosage form and methods of administering► Subscribe
7,862,832Generally linear effervescent oral fentanyl dosage form and methods of administering► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,862,833

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel176452► Subscribe
Japan2007517053► Subscribe
South Korea20060127944► Subscribe
South Korea101184138► Subscribe
MexicoPA06007453► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Baxter
Accenture
UBS
US Department of Justice
Julphar
Daiichi Sankyo
McKinsey
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot